Larissa A. Korde

10.7k citations

81 papers · 3.7k indexed · 2 hit papers · h-index 27

Oncology top 1%
Cancer Research top 2%
Genetics top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology top 10%

Co-authors: Stacey Shiovitz Mark H. Greene Dawn L. Hershman Mark R. Somerfield Julie R. Gralow Lisa A. Carey Meredith M. Regan Patricia A. Spears
Topics: Breast Cancer Treatment Studies (18 papers)Cancer Risks and Factors (17 papers)Testicular diseases and treatments (12 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology American Journal of Clinical Nutrition JNCI Journal of the National Cancer Institute
Partner nations: United States Switzerland Germany

In The Last Decade

Larissa A. Korde

75 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

2021 592 citations Larissa A. Korde, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

2016 446 citations Larissa A. Korde et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Larissa A. Korde

Since Specialization

Citations

This map shows the geographic impact of Larissa A. Korde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larissa A. Korde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larissa A. Korde more than expected).

Fields of papers citing papers by Larissa A. Korde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larissa A. Korde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larissa A. Korde. The network helps show where Larissa A. Korde may publish in the future.

Co-authorship network of co-authors of Larissa A. Korde

This figure shows the co-authorship network connecting the top 25 collaborators of Larissa A. Korde. A scholar is included among the top collaborators of Larissa A. Korde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larissa A. Korde. Larissa A. Korde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801 2025 ·Annals of Oncology ·Sapna P. Patel,(unknown),Víctor M. Prieto,M. J. S. Lowe,Elizabeth I. Buchbinder,Yuanbin Chen,G. Paul Wright,John Hyngstrom,(unknown),(unknown),(unknown),Kari Kendra,Craig Devoe,Ankit Mangla,Alexandra P. Ikeguchi,(unknown),Larissa A. Korde,James J. Moon,Vernon K. Sondak,(unknown)	0
2	LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial 2025 ·Annals of Oncology ·(unknown),Samuel M. Niman,Marco Ruggeri,Fedro A. Peccatori,Hatem A. Azim,(unknown),C. Saura Manich,Chikako Shimizu,(unknown),(unknown),Erica T. Warner,Audrey Mailliez,Frédéric Amant,(unknown),Martine Piccart,Larissa A. Korde,Aron Goldhirsch,R.D. Gelber,AH Partridge	0
3	Prospective Integration of Patient Preferences Into Adjuvant Therapy Decisions for Older Women With Early-Stage Hormone Receptor-Positive Breast Cancer Adjuvant Therapy Decisions in Breast Cancer 2025 ·Practical Radiation Oncology ·Andrea M. Brown,Sara R. Alcorn,Victoria Croog,(unknown),Mary Wilkinson,(unknown),Larissa A. Korde,Maureen O’Donnell,(unknown),C.-F. Westin,Jean L. Wright	0
4	COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS) 2023 ·JNCI Journal of the National Cancer Institute ·Ana F. Best,(unknown),Jessica Li,(unknown),Andrea Denicoff,(unknown),Larry Rubinstein,Jeremy L. Warner,Brian I. Rini,Larissa A. Korde	4
5	LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801 2023 ·Annals of Oncology ·Sapna P. Patel,Megan Othus,Paul Wright,John Hyngstrom,Christopher D. Lao,(unknown),Sunandana Chandra,Kari Kendra,Craig Devoe,Aparna Hegde,Ankit Mangla,Michael Lowe,Elizabeth I. Buchbinder,John M. Kirkwood,Elad Sharon,Larissa A. Korde,James Moon,Vernon K. Sondak,Antoni Ribas,Víctor G. Prieto	7
6	Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update 2022 ·Journal of Clinical Oncology ·Larissa A. Korde,Mark R. Somerfield,Dawn L. Hershman,(unknown)	29
7	Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A 2022 ·JCO Oncology Practice ·Praveen Vikas,Larissa A. Korde,Mark R. Somerfield,Dawn L. Hershman	6
8	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guidelinebreakdown → 2021 ·Journal of Clinical Oncology ·Larissa A. Korde,Mark R. Somerfield,Lisa A. Carey,Jennie R. Crews,Neelima Denduluri,E. Shelley Hwang,Seema A. Khan,Sibylle Loibl,Elizabeth A. Morris,Alejandra Perez,Meredith M. Regan,Patricia A. Spears,Preeti Sudheendra,W. Fraser Symmans,Rachel L. Yung,Brittany Harvey,Dawn L. Hershman	592
9	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. 2020 ·Journal of Clinical Oncology ·X. Cynthia,Vera J. Suman,A. Marilyn Leitch,Souzan Sanati,Kiran Vij,Gary Unzeitig,Jeremy Hoog,Mark A. Watson,Olwen Hahn,J. Michael Guenther,Abigail S. Caudle,Travis Dockter,Larissa A. Korde,Anna Weiss,Kelly K. Hunt,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Lisa A. Carey,Matthew J. Ellis,(unknown)	27
10	Sex Hormones in Women With Elevated Breast Cancer Risk Undergoing Weight Loss 2019 ·Western Journal of Nursing Research ·(unknown),Claire J. Han,(unknown),Larissa A. Korde,(unknown),(unknown),Dale Whittington,Kerryn W. Reding	6
11	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial 2019 ·Breast Cancer Research and Treatment ·Matteo Lambertini,Christine Campbell,Richard D. Gelber,Giuseppe Viale,Ann E. McCullough,Florentine Hilbers,Larissa A. Korde,(unknown),Saranya Chumsri,Christian Jackisch,Antonio C. Wolff,Inês Vaz-Luís,Arlindo R. Ferreira,Aleix Prat,Alvaro Moreno‐Aspitia,Martine Piccart,Sherene Loi,Evandro de Azambuja	26
12	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib 2018 ·Clinical Breast Cancer ·(unknown),Hannah M. Linden,Vijayakrishna K. Gadi,Larissa A. Korde,Eve T. Rodler,Julie R. Gralow,Mary W. Redman,Kelsey K. Baker,Qian Wu,Isaac Jenkins,Brenda F. Kurland,Mitchell Garrison,Julie C. Smith,Jeanne E. Anderson,(unknown),Jennifer M. Specht	29
13	Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer 2017 ·Journal of Adolescent and Young Adult Oncology ·Shoshana M. Rosenberg,Shari Gelber,Richard D. Gelber,(unknown),Larissa A. Korde,Olivia Pagani,Ann H. Partridge	25
14	Solitary Orbital Metastasis 35 Years after a Diagnosis of Lobular Carcinoma in Situ 2017 ·Cureus ·Matthew B. Spraker,Courtney E. Francis,Larissa A. Korde,(unknown),Lia M. Halasz	5
15	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer 2016 ·Clinical Cancer Research ·Eve T. Rodler,Brenda F. Kurland,Melissa Griffin,Julie R. Gralow,Peggy L. Porter,Rosa F. Yeh,Vijayakrishna K. Gadi,Jamie Guenthoer,Jan H. Beumer,Larissa A. Korde,Sandra Strychor,Brian F. Kiesel,Hannah M. Linden,John A. Thompson,Elizabeth M. Swisher,Xiaoyu Chai,Stacie Peacock Shepherd,Vincent L. Giranda,Jennifer M. Specht	69
16	Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting 2015 ·Journal of Adolescent and Young Adult Oncology ·Larissa A. Korde,Ann H. Partridge,(unknown),(unknown),(unknown),Rebecca H. Johnson	12
17	Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial 2014 ·American Journal of Clinical Nutrition ·Caitlin Mason,Liren Xiao,Ikuyo Imayama,Catherine Duggan,Ching-Yun Wang,Larissa A. Korde,Anne McTiernan	114
18	Current treatment options in triple negative breast cancer 2011 ·Breast Disease ·Eve T. Rodler,Larissa A. Korde,Julie R. Gralow	38
19	Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors 2009 ·Cancer Research ·Anélia Horvath,Larissa A. Korde,Mark H. Greene,Rossella Libé,(unknown),Fábio R. Faucz,Marie Laure Raffin‐Sanson,Kit Man Tsang,Limor Drori-Herishanu,(unknown),Elaine F. Remmers,(unknown),(unknown),J Greene,Maria Nesterova,Maria J. Merino,Jérôme Bertherat,Constantine A. Stratakis	61
20	Recruitment to a physical activity intervention study in women at increased risk of breast cancer 2009 ·BMC Medical Research Methodology ·Larissa A. Korde,(unknown),Ashley Wilder Smith,David Venzon,Sheila A. Prindiville,Bart Drinkard,Nancy G. Sebring,Marcia Datlow Smith,Jo Anne Zujewski,Jennifer Eng‐Wong	12

About Larissa A. Korde

Larissa A. Korde is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 81 papers that have together received 3.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (18 papers), Cancer Risks and Factors (17 papers) and Testicular diseases and treatments (12 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.7k citations) and Pathology and Forensic Medicine (681 citations). Larissa A. Korde has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Stacey Shiovitz, Mark H. Greene, Dawn L. Hershman, Mark R. Somerfield, Julie R. Gralow, Lisa A. Carey, Meredith M. Regan, Patricia A. Spears, Neelima Denduluri and Sibylle Loibl. Their work appears in journals such as Journal of Clinical Oncology, American Journal of Clinical Nutrition and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact